Ianalumab

• CAT Number: I041842
• CAS Number: 1929549-92-7
• Purity: ≥95%

Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM)[1].
Ianalumab (0.1 μg/mL; 72 h) shows enhanced ADCC and cytokine production induction by chronic lymphocytic leukemia (CLL) NK cells[1].
Ianalumab (Total: 100 mg/kg; once weekly for 2 weeks) increases in vivo survival in CLL mouse models[1].
Ianalumab (10 mg/kg; once weekly for 6 weeks) is enhanced by Ibrutinib (HY-10997) through an ITAM function on NK cells[1].

Reference

[1]. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460.
 [Content Brief]